Tegafur + Gimeracil + Oteracil

Thông tin thuốc gốc
Chỉ định và Liều dùng
Gastric cancer
Adult: Available preparations:
Tegafur 15 mg, gimeracil 4.35 mg and oteracil 11.8 mg
Tegafur 20 mg, gimeracil 5.8 mg and oteracil 15.8 mg
Patient w/ advanced cases: In combination w/ cisplatin: 25 mg/m2 (expressed as tegafur content) bid for 21 days followed by 7 days rest. Repeat treatment cycle every 4 wk. Dosage may reduce w/ each cycle or w/in a cycle based on toxicity.
Renal Impairment
CrCl (mL/min) Dosage
<30 Not recommended.
30-50 20 mg/m2 (expressed as tegafur content) bid.
Hepatic Impairment
Severe: Not recommended.
Chống chỉ định
History of severe and unexpected reactions to fluoropyrimidine therapy. DPD deficiency, severe bone marrow suppression (e.g. neutropaenia, leukopaenia or thrombocytopaenia), ESRD requiring dialysis. Pregnancy and lactation. Concomitant use w/ other fluopyrimidines and use w/in 4 wk treatment of DPD inhibitors.
Thận trọng
Severe hepatic and renal impairment (CrCl <30 mL/min).
Phản ứng phụ
Significant: Bone marrow suppression (e.g. neutropaenia, leukopaenia, thrombocytopaenia, anaemia and pancytopaenia), acute renal failure, diarrhoea, dehydration, electrolyte disturbance, lacrimal disorders (e.g. increased lacrimation, dry eye, dacryostenosis).
Nervous: Peripheral neuropathy, dizziness, headache, fatigue, asthenia, insomnia.
CV: Hypotension, DVT, HTN, peripheral oedema.
GI: Nausea, vomiting, anorexia, dysgeusia, stomatitis, dry mouth, flatulence, dyspepsia, abdominal discomfort/pain, dysphagia, GI inflammation, GI haemorrhage.
Resp: Dyspnoea, epistaxis, hiccups, cough.
Hepatic: Hyperbilirubinaemia, increased ALT and AST.
Genitourinary: Hyperuricaemia.
Endocrine: Wt loss.
Musculoskeletal: Musculoskeletal pain.
Otic: Hearing impairment, deafness.
Ophthalmologic: Vision disorders (e.g. blurred vision, diplopia, photopsia, decreased visual acuity, blindness), conjunctivitis.
Dermatologic: Palmar-plantar erythrodysaesthesia syndrome, rash, pruritus, hyperpigmentation, dry skin, alopecia.
Others: Mucosal inflammation, pyrexia, chills.
Thông tin tư vấn bệnh nhân
This drug may cause blurred vision, dizziness, fatigue and nausea, if affected, do not drive or operate machinery.
Monitor haematology, renal (e.g. serum creatinine, CrCl) function, hepatic function and serum electrolytes.
Quá liều
Symptoms: Nausea, vomiting, diarrhoea, mucositis, GI irritation, bleeding, bone marrow depression and resp failure. Management: Supportive treatment.
Tương tác
Increased risk of bleeding w/ coumarin-derivative anticoagulants. Increased myelotoxicity and haematologic toxicity w/ clozapine. Increased adverse effects and toxicities w/ cimetidine, folinic acid metabolites, methotrexate and nitroimidazoles. Decreased efficacy w/ CYP2A6 inhibitors and allopurinol. Increased plasma concentration and toxicity w/ phenytoin.
Potentially Fatal: Increased serum level concentration and toxicities w/ other fluoropyrimidines (e.g. capecitabine, flucytosine, 5-FU) and DPD inhibitors (e.g. sorivudine, brivudine).
Food Interaction
Decreased exposure of gimeracil and oteracil.
Tác dụng
Description: Tegafur: Tegafur, a fluoropyrimidine antimetabolite agent, is a prodrug of 5-fluorouracil which forms an active metabolite, 5-fluoro-deoxyuridine-monophosphate (FdUMP). FdUMP and reduced folate binds to thymidylate synthase forming a ternary complex leading to inhibition of DNA synthesis.
Gimeracil: Gimeracil inhibits dihydropyrimidine dehydrogenase (DPD), the main enzyme degrading 5-FU, thereby increasing 5-FU exposure and anti-tumour activity.
Oteracil: Oteracil inhibits orotate phosphoribosyltransferase (OPRT), an enzyme thought to play a role in the GI toxicity of 5-FU, thereby decreasing toxicity of 5-FU in GI mucosa.
Absorption: Tegafur: Well absorbed from the GI tract. Time to peak plasma concentration: 0.5-0.8 hr; 2 hr (5-FU).
Gimeracil: Time to peak plasma concentration: 1 hr.
Oteracil: Time to peak plasma concentration: 2 hr.
Distribution: Tegafur: Crosses blood-brain barrier and distributed in the CSF. Volume of distribution: 16 L/m2. Plasma protein binding: 52.3%; 18.4% (5-FU).
Gimeracil: Volume of distribution: 17 L/m2. Plasma protein binding: 32.2%.
Oteracil: Distributed into GI tract tissues. Volume of distribution: 23 L/m2. Plasma protein binding: 8.4%.
Metabolism: Tegafur: Metabolised in the liver by CYP2A6 into 5-FU which is further metabolised via phosphorylation into FdUMP (active).
Excretion: Tegafur: Via urine (3.8-4.2% as unchanged drug, 9.5-9.7% as 5-FU). Elimination half-life: 6.7-11.3 hr; 1.6-1.9 hr (5-FU).
Gimeracil: Via urine (65-72% as unchanged drug). Elimination half-life: 3.1-4.1 hr.
Oteracil: Via urine (3.5-3.9% as unchanged drug). Elimination half-life: 1.8-9.5 hr.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Tegafur, CID=5386, https://pubchem.ncbi.nlm.nih.gov/compound/Tegafur (accessed on Jan. 23, 2020)

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Gimeracil, CID=54679224, https://pubchem.ncbi.nlm.nih.gov/compound/Gimeracil (accessed on Jan. 23, 2020)

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Oxonic Acid, CID=4604, https://pubchem.ncbi.nlm.nih.gov/compound/Oxonic-Acid (accessed on Jan. 23, 2020)

Bảo quản
This is a cytotoxic drug. Any unused portions should be disposed of in accordance w/ local requirements.
Phân loại MIMS
Buckingham R (ed). Gimeracil. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/08/2017.

Buckingham R (ed). Oteracil. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/08/2017.

Buckingham R (ed). Tegafur. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/08/2017.

Joint Formulary Committee. Tegafur with Gimeracil and Oteracil. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/08/2017.

Teysuno 15 mg/4.35 mg/11.8 mg and 20 mg/5.8 mg/15.8 mg Hard Capsules (Nordic Group BV). European Medicines Agency [online]. Accessed 15/08/2017.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Tegafur + Gimeracil + Oteracil từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in